BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
[ad_1] To the Editor Walter et al. (Jan. 6 issue)1 report the results of a randomized, controlled trial showing that two doses of the messenger RNA (mRNA) vaccine BNT162b2 against Covid-19 were safe, immunogenic, and efficacious in children 5 to 11 years of age. However, this trial was not powered to detect potential serious side […]
Continue Reading